These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 10585223)

  • 1. Physiologically based pharmacokinetics of digoxin in mdr1a knockout mice.
    Kawahara M; Sakata A; Miyashita T; Tamai I; Tsuji A
    J Pharm Sci; 1999 Dec; 88(12):1281-7. PubMed ID: 10585223
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Altered drug disposition of the platelet activating factor antagonist apafant in mdr1a knockout mice.
    Leusch A; Volz A; Müller G; Wagner A; Sauer A; Greischel A; Roth W
    Eur J Pharm Sci; 2002 Aug; 16(3):119-28. PubMed ID: 12128165
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Downregulation of mdr1a expression in the brain and liver during CNS inflammation alters the in vivo disposition of digoxin.
    Goralski KB; Hartmann G; Piquette-Miller M; Renton KW
    Br J Pharmacol; 2003 May; 139(1):35-48. PubMed ID: 12746221
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Compartment-specific roles of ATP-binding cassette transporters define differential topotecan distribution in brain parenchyma and cerebrospinal fluid.
    Shen J; Carcaboso AM; Hubbard KE; Tagen M; Wynn HG; Panetta JC; Waters CM; Elmeliegy MA; Stewart CF
    Cancer Res; 2009 Jul; 69(14):5885-92. PubMed ID: 19567673
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of mdr1a P-glycoprotein gene disruption, gender, and substrate concentration on brain uptake of selected compounds.
    Dagenais C; Zong J; Ducharme J; Pollack GM
    Pharm Res; 2001 Jul; 18(7):957-63. PubMed ID: 11496955
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lack of difference in pulmonary absorption of digoxin, a P-glycoprotein substrate, in mdr1a-deficient and mdr1a-competent mice.
    Manford F; Riffo-Vasquez Y; Spina D; Page CP; Hutt AJ; Moore V; Johansson F; Forbes B
    J Pharm Pharmacol; 2008 Oct; 60(10):1305-10. PubMed ID: 18812023
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Homozygous disruption of the mdrla P-glycoprotein gene affects blood-nerve barrier function in mice administered with neurotoxic drugs.
    Saito T; Zhang ZJ; Ohtsubo T; Noda I; Shibamori Y; Yamamoto T; Saito H
    Acta Otolaryngol; 2001 Sep; 121(6):735-42. PubMed ID: 11678173
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A.
    Schinkel AH; Wagenaar E; van Deemter L; Mol CA; Borst P
    J Clin Invest; 1995 Oct; 96(4):1698-705. PubMed ID: 7560060
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Resolution of P-glycoprotein and non-P-glycoprotein effects on drug permeability using intestinal tissues from mdr1a (-/-) mice.
    Stephens RH; O'Neill CA; Bennett J; Humphrey M; Henry B; Rowland M; Warhurst G
    Br J Pharmacol; 2002 Apr; 135(8):2038-46. PubMed ID: 11959808
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evidence for an active transport of morphine-6-beta-d-glucuronide but not P-glycoprotein-mediated at the blood-brain barrier.
    Bourasset F; Cisternino S; Temsamani J; Scherrmann JM
    J Neurochem; 2003 Sep; 86(6):1564-7. PubMed ID: 12950465
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Full blockade of intestinal P-glycoprotein and extensive inhibition of blood-brain barrier P-glycoprotein by oral treatment of mice with PSC833.
    Mayer U; Wagenaar E; Dorobek B; Beijnen JH; Borst P; Schinkel AH
    J Clin Invest; 1997 Nov; 100(10):2430-6. PubMed ID: 9366556
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efavirenz does not interact with the ABCB1 transporter at the blood-brain barrier.
    Dirson G; Fernandez C; Hindlet P; Roux F; German-Fattal M; Gimenez F; Farinotti R
    Pharm Res; 2006 Jul; 23(7):1525-32. PubMed ID: 16779703
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 1Alpha,25-dihydroxyvitamin D3 up-regulates P-glycoprotein via the vitamin D receptor and not farnesoid X receptor in both fxr(-/-) and fxr(+/+) mice and increased renal and brain efflux of digoxin in mice in vivo.
    Chow EC; Durk MR; Cummins CL; Pang KS
    J Pharmacol Exp Ther; 2011 Jun; 337(3):846-59. PubMed ID: 21421739
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of breast cancer resistance protein and P-glycoprotein on the brain penetration of flavopiridol, imatinib mesylate (Gleevec), prazosin, and 2-methoxy-3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)propanoic acid (PF-407288) in mice.
    Zhou L; Schmidt K; Nelson FR; Zelesky V; Troutman MD; Feng B
    Drug Metab Dispos; 2009 May; 37(5):946-55. PubMed ID: 19225039
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Penetration of endogenous steroid hormones corticosterone, cortisol, aldosterone and progesterone into the brain is enhanced in mice deficient for both mdr1a and mdr1b P-glycoproteins.
    Uhr M; Holsboer F; Müller MB
    J Neuroendocrinol; 2002 Sep; 14(9):753-9. PubMed ID: 12213137
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of itraconazole on the pharmacokinetics of digoxin in guinea pigs.
    Nishihara K; Hibino J; Kotaki H; Sawada Y; Iga T
    Biopharm Drug Dispos; 1999 Apr; 20(3):145-9. PubMed ID: 10211867
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kinetic analysis of the cooperation of P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp/Abcg2) in limiting the brain and testis penetration of erlotinib, flavopiridol, and mitoxantrone.
    Kodaira H; Kusuhara H; Ushiki J; Fuse E; Sugiyama Y
    J Pharmacol Exp Ther; 2010 Jun; 333(3):788-96. PubMed ID: 20304939
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development and Characterization of MDR1 (
    Liang C; Zhao J; Lu J; Zhang Y; Ma X; Shang X; Li Y; Ma X; Liu M; Wang X
    Drug Metab Dispos; 2019 Feb; 47(2):71-79. PubMed ID: 30478157
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mdr1a, Bcrp and Mrp2 regulate the efficacy and toxicity of mesaconitine and hypaconitine by altering their tissue accumulation and in vivo residence.
    Li X; Ou X; Luo G; Ou X; Xie Y; Ying M; Qu W; Zuo H; Qi X; Wang Y; Liu Z; Zhu L
    Toxicol Appl Pharmacol; 2020 Dec; 409():115332. PubMed ID: 33171190
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tissue distribution of indinavir administered as solid lipid nanocapsule formulation in mdr1a (+/+) and mdr1a (-/-) CF-1 mice.
    Pereira de Oliveira M; Garcion E; Venisse N; Benoit JP; Couet W; Olivier JC
    Pharm Res; 2005 Nov; 22(11):1898-1905. PubMed ID: 16132350
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.